Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XNW5004 and Pembrolizumab in Advanced Solid Tumors
NCT06022757Phase 2Terminated
- Sponsor
- Evopoint Biosciences
- Start
- Sep 2023
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of igermetostat in solid tumor, head and neck squamous cell carcinoma (HNSCC), urothelial carcinoma (UC), prostate cancer (PCa), small cell lung cancer (SCLC), sponsored by Evopoint Biosciences. Started Sep 2023; status: terminated.
02
Drugs
igermetostat
03
Conditions
solid tumorhead and neck squamous cell carcinoma (HNSCC)urothelial carcinoma (UC)prostate cancer (PCa)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06022757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06022757.